Smoking, Headaches And Allergies: Rx Pipeline Drugs May Impact OTCs
This article was originally published in The Tan Sheet
Executive Summary
Pfizer and Schering-Plough are developing a number of new prescription drugs and line extensions that could make inroads into large OTC categories
You may also be interested in...
Claritin Growth Plateaus As Schering Moves Ahead With Consent Decree
Sales of Schering-Plough's Claritin (loratadine) appear to have leveled off following a strong 2003 campaign for the over-the-counter antihistamine
Pfizer Ad Says OTCs “Aren’t As Safe As You Might Think”
A new website from Pfizer touting the firm's COX-2 pain reliever Celebrex (celecoxib) questions the perceived safety profile of over-the-counter drugs
Pfizer Touts Relpax Efficacy Versus Excedrin Migraine In Study
Pfizer is targeting the competition from OTC analgesics in a recently published study on the superior efficacy of its Relpax (eletriptan) versus Bristol-Myers Squibb's Excedrin Migraine